The typical genomic feature of acute myeloid leukemia (AML) M3 subtype is the fusion event of PML/RARα, and ATRA/ATO-based combination therapy is current standard treatment regimen for M3 subtype.
Source link
You may also like
Research on eight machine learning algorithms applicability on different characteristics data sets in medical classification tasks
Beyond Stochastic Parrots: The Emerging Reasoning Capacities of Large Language Models
Nvidia, Databricks investments value generative AI search startup at $520M
Evaluating the Performance of AI-Based Large Language Models in Radiation Oncology
Exploring the Metaverse: A Guide to Extended Reality
